Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis
Crossref DOI link: https://doi.org/10.1007/s40744-017-0090-2
Published Online: 2017-12-05
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kivitz, Alan
Baret-Cormel, Lydie
van Hoogstraten, Hubert
Wang, Sheldon
Parrino, Janie
Xu, Christine
Stanislav, Marina
Funding for this research was provided by:
Sanofi Genzyme
Regeneron Pharmaceuticals